Psyence BioMed’s Innovative Partnership with PsyLabs
Psyence Biomedical Ltd. (NASDAQ: PBM) has embarked on an exciting chapter in the realm of psychedelic medicine. Collaborating with PsyLabs, a pioneer in producing and extracting psychedelic compounds, Psyence BioMed recently celebrated a significant breakthrough in high-purity Ibogaine production. This accomplishment marks a milestone in Psyence's commitment to scalably and sustainably offer nature-based psychedelic treatments for various mental health conditions.
Achievements in Production and Safety Standards
PsyLabs has recently delivered a GMP-aligned Ibogaine Total Alkaloid extract, meeting rigorous microbial safety standards suitable for food-grade consumption. This development underscores the efficacy of ongoing investments by Psyence BioMed into PsyLabs, which began with an equity stake acquisition in recent years, emphasizing a strong bond with greater potential for innovation in the psychedelic industry.
Commitment to Quality and Sustainability
Cody Robyn Futeran, the Head of Extraction Innovations and Business Development at PsyLabs, expressed immense pride in his team's accomplishments, highlighting their dedication to extracting naturally derived, sustainable materials while adhering to strict Good Manufacturing Practices (GMP). This achievement not only showcases their manufacturing capabilities but also their resolve to produce safe, consumable medications which can meet growing global requirements.
Expanding the Horizons of Psychedelic Pharmaceuticals
As Tony Budden, CEO of PsyLabs, noted, this success reflects their cutting-edge facilities and relentless pursuit of innovation aimed at increasing the purity of their extracts. The demand for high-quality psychedelic Active Pharmaceutical Ingredients (APIs) continues to soar, prompting PsyLabs to expand its chemistry production area to better supply Ibogaine HCL and other high-purity products sourced from both iboga and mushrooms.
Global Availability of Psychedelic Ingredients
PsyLabs is dedicated to ensuring that their Ibogaine product is readily available to licensed research institutions and developers globally. By positioning itself as a reliable supplier committed to ethical sourcing, PsyLabs is carving out a significant place in the rapidly changing landscape of psychedelic pharmaceuticals.
About PsyLabs and Its Operations
PsyLabs operates within the realms of psychedelic API development. The company is federally licensed to cultivate and extract psilocybin mushrooms alongside other psychedelic compounds like ibogaine, mescaline, and DMT. Its commitment to safety and quality is enhanced by its operations in an ISO 22000-certified facility, assuring the highest standards for safety and traceability.
PsyLabs continues to nurture its vision of natural compound purification and is expanding its product pipeline to include ibogaine and various next-generation psychedelics. Its successful international exports of psilocybin products to markets in Canada, the UK, Portugal, and Slovenia are evidences of its operational capabilities and market reach.
About Psyence BioMed
Psyence Biomedical Ltd. stands out as one of the few vertically integrated biopharmaceutical companies specializing in psychedelic-based therapies listed on NASDAQ. The company focuses on developing nature-derived psilocybin and ibogaine-based medicines to address pressing mental health issues. With a name that blends 'psychedelics' and 'science', Psyence emphasizes its scientific approach to ensuring safe and effective treatments for mental health disorders.
The company continues its mission to meet the unmet mental health needs, particularly focusing on palliative care solutions.
Frequently Asked Questions
What is the latest achievement of Psyence BioMed?
Psyence BioMed has successfully partnered with PsyLabs to produce a high-purity Ibogaine extract that meets food-grade safety standards.
Who is PsyLabs?
PsyLabs is a psychedelic API development company focusing on producing psychedelic compounds safely and sustainably, holding federal licensing for cultivation and extraction.
What are psychedelic APIs?
Psychedelic Active Pharmaceutical Ingredients (APIs) are refined compounds derived from naturally occurring psychedelic substances, utilized in developing therapeutic medications.
Where can PsyLabs' products be obtained?
Ibogaine and other psychedelic products from PsyLabs will be made available to licensed research institutions and developers globally.
What is Psyence BioMed's mission?
Psyence BioMed aims to address unmet mental health needs through the creation of nature-derived psychedelic therapies, particularly focusing on enhancing patient care.
